{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:26:02Z","timestamp":1787109962686,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105359","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:40:50Z","timestamp":1778812850000},"page":"105359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of systemic regimens for resectable gastric and gastroesophageal junction adenocarcinoma: A network meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8617-966X","authenticated-orcid":false,"given":"Rafael Lara","family":"Nohmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isadora","family":"Mamede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turkan","family":"Aliyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhenan","family":"Hoffmann Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Barbosa e","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson Ruiz","family":"Simoes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo dos Santos","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus de Oliveira","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105359_bib1","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"Al-Batran","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib2","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105359_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf157","article-title":"Efficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal junction adenocarcinoma: a network meta-analysis","volume":"30","author":"Anjum","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105359_bib4","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/annonc\/mdx236","article-title":"Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin\/S-1 and docetaxel\/cisplatin\/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer","volume":"28","author":"Aoyama","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/annonc\/mdf040","article-title":"Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group","volume":"13","author":"Bajetta","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial","volume":"379","author":"Bang","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105359_bib7","first-page":"24","article-title":"Comparing efficacy of preoperative neo-adjuvant chemotherapy and surgery versus surgery alone in patients with resectable gastroesophageal cancer","volume":"7","author":"Basi","year":"2013","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"10.1016\/j.critrevonc.2026.105359_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101223","article-title":"Novel insights into taxane pharmacology: an update on drug resistance mechanisms, immunomodulation and drug delivery strategies","volume":"81","author":"Beretta","year":"2025","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.critrevonc.2026.105359_bib9","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/annonc\/mdi270","article-title":"Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801)","volume":"16","author":"Bouch\u00e9","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.amjsurg.2003.12.014","article-title":"Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer","volume":"187","author":"Chipponi","year":"2004","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105359_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105359_bib12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1470-2045(17)30043-8","article-title":"Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2\u20133 trial","volume":"18","author":"Cunningham","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/jnci\/djn054","article-title":"Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC","volume":"100","author":"Di Costanzo","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105359_bib14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/annonc\/mdv620","article-title":"Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43\/99 phase III trial","volume":"27","author":"Fazio","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.34495","article-title":"Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: a randomized phase II\/III trial of the German AIO and Italian GOIM","volume":"153","author":"Goetze","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105359_bib17","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105359_bib18","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ags3.12352","article-title":"Primary results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin\/S-1 and docetaxel\/cisplatin\/S-1 as neoadjuvant chemotherapy for advanced gastric cancer","volume":"4","author":"Hayashi","year":"2020","journal-title":"Ann. Gastroenterol. Surg."},{"key":"10.1016\/j.critrevonc.2026.105359_bib19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa2409408","article-title":"Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer","volume":"392","author":"Hoeppner","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105359_bib20","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO-25-01439","article-title":"KEYNOTE-585 fails while Matterhorn succeeds in gastric cancer: what lessons can we learn?","volume":"43","author":"Ilson","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib21","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ejso.2010.06.012","article-title":"Prospective randomized trial of short-term neoadjuvant chemotherapy for advanced gastric cancer","volume":"36","author":"Imano","year":"2010","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074495","article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","volume":"381","author":"Izcovich","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105359_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105359_bib24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10120-024-01471-z","article-title":"Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial","volume":"27","author":"Jiang","year":"2024","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.critrevonc.2026.105359_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010960","article-title":"Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy","volume":"13","author":"Kalinski","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105359_bib26","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"Kang","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib27","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa2405195","article-title":"Preoperative chemoradiotherapy for resectable gastric cancer","volume":"391","author":"Leong","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105359_bib28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1001\/jamasurg.2022.0182","article-title":"Surgical management of gastric cancer: a review","volume":"157","author":"Li","year":"2022","journal-title":"JAMA Surg."},{"key":"10.1016\/j.critrevonc.2026.105359_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35831","article-title":"Perioperative chemotherapy for gastric cancer patients with microsatellite instability or deficient mismatch repair: a systematic review and meta-analysis","volume":"131","author":"Liu","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105359_bib30","article-title":"Combinatorial regimens of chemotherapeutic agents: a new perspective on raising the heat of the tumor immune microenvironment","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105359_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan\u2013Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.critrevonc.2026.105359_bib32","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001489","article-title":"Neoadjuvant therapy of DOF regimen plus bevacizumab can increase surgical resection rate in locally advanced gastric cancer: a randomized, controlled study","volume":"94","author":"Ma","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.critrevonc.2026.105359_bib33","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.3390\/cancers12102790","article-title":"Preoperative or perioperative docetaxel, oxaliplatin, and capecitabine (GASTRODOC Regimen) in patients with locally-advanced resectable gastric cancer: a randomized phase-II trial","volume":"12","author":"Monti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105359_bib34","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","article-title":"Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial","volume":"15","author":"Noh","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib35","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12029-026-01418-w","article-title":"Perioperative chemoimmunotherapy vs. chemotherapy alone for gastroesophageal cancer: a systematic review and meta-analysis","volume":"57","author":"Rodrigues","year":"2026","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105359_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103494","article-title":"Neoadjuvant FLOT versus SOX chemotherapy in locally advanced gastric cancer: secondary outcomes of a single-centre, open-label, randomised, exploratory phase 2 trial","volume":"88","author":"Sah","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2026.105359_bib38","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1038\/s41467-020-19965-6","article-title":"Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer","volume":"11","author":"Sah","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105359_bib39","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2009.26.6114","article-title":"Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954","volume":"28","author":"Schuhmacher","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib40","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib41","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO-25-00486","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy as perioperative therapy in locally advanced gastric and gastroesophageal junction cancer: final analysis of the randomized, phase III KEYNOTE-585 study","volume":"43","author":"Shitara","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib42","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib43","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0034-2025","article-title":"Valid surrogate end-points in nonsmall cell lung cancer peri-operative systemic therapy trials: a systematic review","volume":"34","author":"Somekawa","year":"2025","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.critrevonc.2026.105359_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejca.2018.01.079","volume":"93","author":"Stahl","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105359_bib45","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ 366"},{"key":"10.1016\/j.critrevonc.2026.105359_bib46","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1097\/JS9.0000000000000692","article-title":"Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial","volume":"109","author":"Tian","year":"2023","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105359_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-52334-y","article-title":"Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors","volume":"9","author":"Uson Junior","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105359_bib48","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s40001-022-00878-7","article-title":"The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis","volume":"27","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.critrevonc.2026.105359_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-024-01536-7","article-title":"Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II\/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial","volume":"17","author":"Wang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib50","doi-asserted-by":"crossref","first-page":"516","DOI":"10.21147\/j.issn.1000-9604.2018.05.05","article-title":"Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II\u2013III randomized trial","volume":"30","author":"Xue","year":"2018","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105359_bib51","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103504","article-title":"Effect of neoadjuvant therapy on survival outcomes in patients with melanoma: a systematic review and meta-analysis","volume":"88","author":"Yuan","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2026.105359_bib53","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"Zhang","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib54","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(24)00676-4","volume":"26","author":"Zhang","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib55","volume":"16","author":"Zhang","year":"2026","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib56","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s10147-025-02888-x","article-title":"FLOT vs DOS neoadjuvant chemotherapy in locally advanced gastric cancer: propensity score analysis","volume":"30","author":"Zhang","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105359_bib57","doi-asserted-by":"crossref","first-page":"236","DOI":"10.31083\/ph.2017.6865","article-title":"Short-term curative effect of S-1 plus oxaliplatin as perioperative chemotherapy for locally advanced gastric cancer: a prospective comparison study","volume":"72","author":"Zhao","year":"2017","journal-title":"Pharmazie"},{"key":"10.1016\/j.critrevonc.2026.105359_bib58","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1002\/cam4.3224","article-title":"The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: a multicenter randomized clinical trial","volume":"9","author":"Zhao","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.critrevonc.2026.105359_bib59","unstructured":"Zhu, Y., Zhang, Z.Y., Zou, X., 2020. Comparative study of tegafur gimeracil and oteracil potassium (TS-1) plus docetaxel and oxaliplatin versus TS-1 plus oxaliplatin in postoperative adjuvant chemotherapy for gastric cancer. \u3008https:\/\/api.semanticscholar.org\/CorpusID:222355994\u3009."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:41:01Z","timestamp":1787107261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826002465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":59,"alternative-id":["S1040842826002465"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105359","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of systemic regimens for resectable gastric and gastroesophageal junction adenocarcinoma: A network meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105359"}}